Ichnos Glenmark Innovation (IGI), our wholly owned subsidiary, is working towards delivering treatments for hematalogical malignancies and solid tumors.
Our research and focus on targeted therapies, immuno-oncology assets, biologics combined with global partnerships have helped us accelerate access to transformational therapies across the globe to make a meaningful impact on patient lives. Our robust pipeline reflects our dedication to advancing cancer care globally.
Our footprint in Oncology reflects the convergence of science, collaborations and purpose –
backed by longstanding R&D, a diversified portfolio, and partnerships that expand global reach.
2
Decades of research in cancer care
5
Strategic collaborations
